Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News INmune Bio Inc INMB

Healthcare Biotechnology
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to... see more

Recent & Breaking News (NDAQ:INMB)

INmune Bio Inc. to Join Russell 3000® Index

GlobeNewswire May 30, 2024

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

GlobeNewswire May 9, 2024

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

GlobeNewswire May 7, 2024

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro(TM) Under Compassionate Use for Over Three Years

GlobeNewswire April 30, 2024

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune(TM) Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire April 29, 2024

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire April 25, 2024

INmune Bio Inc. Announces 24-Month Stability Validation of XPro(TM) for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

GlobeNewswire April 23, 2024

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

GlobeNewswire April 22, 2024

INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

GlobeNewswire April 8, 2024

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

GlobeNewswire March 28, 2024

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

GlobeNewswire March 26, 2024

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

GlobeNewswire March 13, 2024

INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro(TM)

GlobeNewswire March 5, 2024

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire February 12, 2024

INmune Bio to Participate in Baird's Biotech Discovery Series Webcast on February 13, 2024

GlobeNewswire February 6, 2024

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program

GlobeNewswire January 30, 2024

ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology

GlobeNewswire January 16, 2024

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune(TM) in Patients with Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire January 2, 2024

INmune Bio Provides Update Regarding Global Alzheimer's Phase II Clinical Trial and Clinical Hold Issued by the United States FDA

GlobeNewswire December 18, 2023

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

GlobeNewswire November 29, 2023